Abstract Library

#3398 Patient-derived tumoroids phenocopy original gastro-entero-pancreatic neuroendocrine neoplasms and facilitate in vitro drug screening

Introduction: GastroEnteroPancreatic Neuroendocrine Neoplasms (GEP-NENs) are rare cancers that appear clinically and biologically extremely heterogenous. While highly proliferative cases are invariably lethal, slower-proliferating NENs—representing predominant cases—have unpredictable clinical courses varying from indolent to malignant. Recent comprehensive NGS screens in patients helped to extend our understanding. However, complementary relevant preclinical models to address disease heterogeneity and to investigate patient-specific treatment alternatives are still inexistent.

Conference:

Presenting Author: April-Monn S

Authors: April-Monn S, Kirchner P, Detjen K, Gloor B, Partelli S,

Keywords: GEP-NEN, Organoid, Tumoroid, Model, Drug screening, translational, single-cell RNAseq, NGS, OMICs, biomarker,

#3326 Drug sensitivity profiles of PNET, SBNET and NEC spheroids

Introduction: Neuroendocrine neoplasms (NENs) are rare cancers that arise from neuroendocrine cells. NENs are classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Few mutations have been identified for NETs from the small bowel (SBNETs) and pancreas (PNETs). SBNETs and PNETs are generally slow growing but they commonly metastasize to the liver and can become aggressive cancers. NECs often harbour mutations in key cell cycle genes (TP53 and RB) and are highly proliferative. Little is known about the drug sensitivity profile of SBNET, PNET and NECs due to the lack of cellular and animal models of these malignancies. Recently, we have developed a protocol to culture NET and NEC cells from patient tumors as patient-derived spheroids and showed that they express NEN markers.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ear P

Authors: Ear P, Tran C, Li G, Abusada E, Mudd J,

Keywords: PNET, SBNET, NEC, drug testing, spheroids,

#3246 Baseline albumin and neutrophil-to-lymphocyte ratio as predictive biomarkers of response to platinum-based therapy in patients with highly proliferative neuroendocrine carcinomas

Introduction: Neuroendocrine carcinomas (NECs) with ki-67/MIB1>55% show different responses to platinum-based therapy. Loss of Rb protein and KRAS mutation are markers of response, but it is unknown whether also clinical factors may have a predictive role.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Colombo E

Authors: Colombo E, Manca P, Prinzi N, Torchio M, Corti F,

Keywords: neuroendocrine carcinoma, albumin, neutrophil-to-lymphocyte ratio, neutropenia, platinum-based therapy, predictive biomarker, clinical biomarker, NECs,

#3113 Small cell neuroendocrine carcinoma of vagina - Rare, aggressive but curable?

Introduction: Small cell neuroendocrine carcinoma (SCNC) is a highly proliferative disease. It commonly affects lung and only 2.5-5% are extrapulmonary. SCNC of vagina is very rare with only 32 published cases in English literature.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Godinho J, Simões P, Leal-Costa L, Baptista C, Casa-Nova M,

Keywords: small cell neuroendocrine carcinoma, vagina, highly proliferative, rare disease,

#1723 Evaluation of the Somatostatin and CXCR4 Chemokine Receptor Expression in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of Different Origin

Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, whereas the chemokine receptor CXCR4 is considered to be present mainly in highly proliferative and advanced tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lupp A

Authors: Mai R, Kaemmerer D, Sänger J, Neubauer E, Schulz S,

Keywords: somatostatin receptor, CXCR4,